Shares in NeuroSearch A/S surged more than 50 percent Friday on news of its largest ever deal, a US$80 million pact with Boehringer Ingelheim GmbH to develop its candidate Alzheimer’s and Parkinson’s drug, NS2330. (BioWorld International)

Irish Government Backs EUR15M Biotech Life Sciences Seed Fund

Feb. 13, 2002

By Cormac Sheridan

NeuroSearch, Ingelheim Enter $80M Alliance Around NS2330

Feb. 13, 2002

By Cormac Sheridan

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...